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Introduction
The COVID-19 pandemic is a global crisis creating severe
disruptions across the economy and health system. Insights
into how to better understand and treat COVID-19 are
desperately needed.
Early studies have focused on the clinical characteristics
[1–3], epidemiology [1, 4, 5], and genomic characterization
[6–8] of SARS-CoV-2 infection. These studies have also
highlighted the value and importance of transparent data
sharing across countries, which have enabled the live track-
ing of the disease widespread worldwide [9, 10]. The role of
host genetics in impacting susceptibility and severity of
COVID-19 has been less studied. Previous work has sup-
ported the role of human leukocyte antigen (HLA) in sus-
ceptibility [11] and severity [12] for several viral infections.
Moreover, a synonymous variant in the IFN-induced trans-
membrane protein-3 gene has been reported to cause severe
clinical outcomes in patients infected with H7N9 and H1N1
influenza viruses [13, 14], although results did not reach
established P value thresholds (P < 5 × 10−8). In addition,
candidate variant studies have suggested host factors that are
critical for severe disease in other coronavirus infections,
such as infections due to the related SARS-CoV [15].
Given the importance and urgency of exploring the role
of the host genome in conjunction with COVID-19 clinical
and genomic variability, and the recognition that this can
only be achieved with the combined effort of the scientific
community, we launched the ‘COVID-19 Host Genetics
Initiative’. This initiative brings together the human
genetics community to generate, share, and analyze data to
learn the genetic determinants of COVID-19 susceptibility,
severity, and outcomes. Such discoveries could help to
identify individuals at unusually high or low risk, generate
hypotheses for drug repurposing, and contribute to global
knowledge of the biology of SARS-CoV-2 infection and
disease. The initiative has three main goals:
1. Provide an environment to foster the sharing of
resources to facilitate COVID-19 host genetics
research (e.g., protocols, questionnaires).
2. Organize analytical activities across studies to identify
genetic determinants of COVID-19 susceptibility and
severity.
3. Provide a platform to share the results from such
activities, as well as the individual-level data where
possible, to benefit the broader scientific community.
Approach
The COVID-19 host genetics initiative is a bottom-up
initiative with a flexible, decentralized structure that is
based on the following collaborative principles:
1. Collaborate in an environment of honesty, fairness,
and trust
2. Promote early-career researchers
3. Respect other groups’ data
4. Operate transparently with a goal of no surprises
5. Seek permission from each group to use results prior
to public release
6. Do not share another group’s results with other parties
without permission
7. The initiative should not inhibit any work being done
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Studies that are interested in joining the initiative can
register via the website1. We can categorize the participat-
ing studies in two main groups. Retrospective collections
are typically biobanks with existing significant genetic data
and active connections to health systems. In these studies,
there is the opportunity to opportunistically and rapidly
develop a genetic study on susceptibility and severity. For
example, in Finland with the national network of biobanks
covering each hospital district, it is possible to acquire
almost ‘real-time’ updates on COVID-19 status of indivi-
duals that are already part of the FinnGen study2. This
group of studies is already connected and loosely structured
via other initiatives such as the Global Biobank Meta-
analysis Initiative3.
The second group of studies includes prospective col-
lection that have recently started to directly consent
incoming COVID-19 patients. More than just the critical
jump in scale for studying progression, severity, and out-
comes, these studies bring important additional opportu-
nities not only for deeper DNA studies, but potentially
informative viral and antibody profiling and epitope map-
ping experiments which can be implemented in many sites
with relatively small blood/plasma requirements.
Data sharing
We expect that a sizable fraction of the studies will be able
to share individual-level data. Genetics and clinical data are
submitted to the European Genome-phenome Archive
(EGA) under controlled access, and this is coordinated with
viral sequence deposition efforts and coordination of other
biomolecular data with EU, EOSC, ELIXIR, and other
institutions across the globe. Alternatively, studies are able
to share summary statistics, which will be directly made
available on the website and via the GWAS catalog [16].
The majority of the planning, discussion, and exchange
of information between the participants study, analysts, and
clinicians is done on a dedicated Slack workspace with the
support of the International Common Disease Alliance
(ICDA)4.
Phenotype and analysis
The initiative aims to support widespread sharing of data
and knowledge across participants groups. Groups can
connect and initiate collaborations focused on specific
phenotypes. Few analyses that can benefit from maximal
sample size are centralized. The primary analysis focuses on
COVID-19 disease severity. There are challenges in defin-
ing COVID-19 severity across multiple studies and
healthcare systems. We used a pragmatic approach which
considers the use of invasive and noninvasive ventilation as
an index of severity. The advantages of this approach is the
possibility to easily retrieve this information from electronic
health records and the widespread use of these procedures
across healthcares. Studies that have collected detailed
clinical information can perform secondary analyses using
continuous markers of disease severity such as maximum
respiratory rate during hospitalization or prior to invasive
respiratory support.
Bioinformatic and statistical analysis will consider data
generated from GWAS array, exome and genome sequen-
cing, leveraging the impact of both common and rare var-
iants. Key analysis will take into account differences
between sexes, ancestries, and date of sample collection.
The latter aspect is important to consider given the rapid
changes in population screening procedures and hospital
capacity with consequent impact on the severity of patients
included in different studies.
Given the importance of the HLA genes system for the
etiology of infectious diseases and autoimmune disorders,
we will impute classical HLA alleles and the corresponding
amino acid sequences. COVID indiscriminately affects
populations from all around the world, and HLA variation is
specific to different populations. Hence, we propose using a
multiethnic HLA reference panel constructed using deep-
coverage whole-genome sequencing data from 21,546
individuals of five different populations: European, African,
Latino, Asian, and South Asian. This reference panel will
capture much of the HLA variation around the world. This
will allow to test each HLA allele and also each of the
amino acid site position within HLA genes to assess if they
explain COVID risk.
Participant studies
At time of writing 105 studies have joined the initiative, and
participation is still expanding. The majority of studies are
conducted in Europe (55%) and the US (28%), amongst
which the United Kingdom (10%) and Italy (9%) are the
largest. However there are also participants from Asia
(Republic of Korea and Malaysia), Australia, the Middle-East
(Kuwait, Pakistan, and Qatar), and Africa (Nigeria); Fig. 1, an
updated list is available on the website5. Most studies (71%)
have initiated a new prospective collection, 27% have done
that on top of existing retrospective collections. Array-based
genotyping is the most common approach, considered by
69% of the participant studies, while exome and genome
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profiling are the two most common additional assays that are
reported by the contributing studies.
Conclusion
We initiated a global effort to study the relationship
between host genome and SARS-CoV-2 infection. Our
approach is inclusive, decentralized, and transparent. While
providing novel scientific insights remains a priority of the
initiative, we equally value the creation of an infrastructure
that facilitates communication between studies with similar
scientific goals. We expect the COVID-19 host genetics
initiative to substantially contribute to the understanding of
the variability of COVID-19 susceptibility, severity, and
outcomes in the population within the next few months.
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